KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Raw Materials (2016 - 2022)

Historic Raw Materials for TherapeuticsMD (TXMD) over the last 11 years, with Q3 2022 value amounting to $1.9 million.

  • TherapeuticsMD's Raw Materials fell 4419.27% to $1.9 million in Q3 2022 from the same period last year, while for Sep 2022 it was $1.9 million, marking a year-over-year decrease of 4419.27%. This contributed to the annual value of $3.0 million for FY2021, which is 1883.67% down from last year.
  • As of Q3 2022, TherapeuticsMD's Raw Materials stood at $1.9 million, which was down 4419.27% from $434000.0 recorded in Q2 2022.
  • TherapeuticsMD's Raw Materials' 5-year high stood at $5.7 million during Q4 2019, with a 5-year trough of $19400.0 in Q4 2018.
  • Moreover, its 5-year median value for Raw Materials was $3.5 million (2021), whereas its average is $2.9 million.
  • Its Raw Materials has fluctuated over the past 5 years, first soared by 2929044.85% in 2019, then tumbled by 9042.58% in 2022.
  • Over the past 5 years, TherapeuticsMD's Raw Materials (Quarter) stood at $19400.0 in 2018, then soared by 29290.45% to $5.7 million in 2019, then tumbled by 34.27% to $3.7 million in 2020, then dropped by 18.84% to $3.0 million in 2021, then crashed by 36.03% to $1.9 million in 2022.
  • Its last three reported values are $1.9 million in Q3 2022, $434000.0 for Q2 2022, and $4.4 million during Q1 2022.